| NCT01792804 | Heinrich-Heine University, Duesseldorf|German Research Foundation | Staphylococcus Aureus Infection | 2013-12 | PHASE3 |
| NCT04775953 | National Institute of Allergy and Infectious Diseases (NIAID) | Staphylococcal Bacteraemia | 2021-04-22 | PHASE2 |
| NCT00638157 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Infective Endocarditis | 2009-02-13 | PHASE4 |
| NCT00467272 | M.D. Anderson Cancer Center|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Bloodstream Infection | 2007-03 | PHASE2 |
| NCT01196169 | Mountain Home Research & Education Corporation|East Tennessee State University|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Staphylococcal Infections|Methicillin-resistant Staphylococcus Aureus | 2010-10 | PHASE4 |
| NCT01184872 | Novartis Pharmaceuticals | Infections | 2010-03 | PHASE3 |
| NCT00538694 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Pneumonia, Bacterial | 2000-10-31 | PHASE3 |
| NCT00858325 | AstraZeneca | Healthy | 2009-02 | PHASE1 |
| NCT01975662 | Singapore General Hospital|Singapore Clinical Research Institute | Bacteremia Due to Staphylococcus Aureus | 2014-01 | PHASE2 |
| NCT03138733 | Basilea Pharmaceutica|Department of Health and Human Services | Staphylococcus Aureus Bacteremia | 2018-08-26 | PHASE3 |
| NCT00093067 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Bacterial Endocarditis|Bacteremia | 2002-03 | PHASE3 |
| NCT06189885 | Chang Gung Memorial Hospital | Periprosthetic Joint Infection | 2024-08-01 | NA |
| NCT01728376 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Bacteremia | 2012-11-29 | PHASE4 |
| NCT06637332 | Todd C. Lee MD MPH FIDSA|University of Melbourne|The Peter Doherty Institute for Infection and Immunity | Staphylococcus Aureus Septicemia|Staphylococcus Aureus Bacteremia|S. Aureus Bacteremia|S. Aureus Bloodstream Infection|Staphylococcus Aureus Endocarditis | 2024-11-14 | PHASE4 |
| NCT00651131 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Wound Infections | 2004-06-01 | PHASE4 |
| NCT00770341 | Merck Sharp & Dohme LLC | Staphylococcal Infection | 2008-09 | PHASE3 |
| NCT02208063 | Cumberland Pharmaceuticals | Bacteremia | 2014-12 | PHASE3 |
| NCT01212432 | University of Zurich | Gram-Positive Bacterial Infections | 2009-12 | PHASE2 |
| NCT03004066 | University Hospital Tuebingen | Heart Assist Device | 2016-10 | |
| NCT02000414 | University Hospital, Caen | Peritoneal Infection | 2013-09 | NA |
| NCT04933344 | Hospices Civils de Lyon | Dactinomycin Adverse Reaction|Bone and Joint Infection | 2021-06-15 | |
| NCT01592032 | Clinica Universidad de Navarra, Universidad de Navarra|University of Navarrra Hospital (Clinica Universitaria) | Catheter-Related Infections|Bacteremia. | 2012-05 | PHASE4 |
| NCT01080963 | Hannover Medical School|Novartis | Wound Infection | 2008-11 | PHASE4 |
| NCT01287832 | St. John Health System, Michigan|Henry Ford Health System|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Bacteremia | 2011-06 | PHASE4 |
| NCT01144000 | Andrej Trampuz|University of Lausanne Hospitals|Kantonsspital Liestal|Schulthess Klinik | Staphylococcal Infections | 2012-06 | PHASE2 |
| NCT01734694 | Henry Ford Health System | Health Care Associated Pneumonia|Osteomyelitis+Septic Arthritis|Endocarditis|Bacteremia|Acute Bacterial Skin and Skin Structure Infections | 2011-10 | PHASE4 |
| NCT03480191 | Centre Hospitalier Universitaire Dijon | Pneumococcal Meningitis | 2018-06-07 | PHASE2 |
| NCT03643952 | Merck Sharp & Dohme LLC | Bacteremia|Soft Tissue Infections|Skin Diseases, Infectious | 2018-12-06 | PHASE2 |
| NCT02142075 | Poitiers University Hospital | Renal Failure|Critical Care|Gram Positive Bacteria | 2014-03 | PHASE3 |
| NCT00430937 | Novartis Pharmaceuticals | Skin Diseases, Infectious|Soft Tissue Infections | 2006-04 | PHASE3 |
| NCT00663403 | University of Michigan|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Critically Ill|Hemodialysis | 2007-02 | PHASE4 |
| NCT01025271 | University of Pittsburgh|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Meningitis | 2010-05 | NA |
| NCT01216241 | University of Rochester|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Febrile Neutropenia | 2011-04 | PHASE3 |
| NCT00295178 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Cellulitis | 2006-02-20 | PHASE4 |
| NCT01171547 | University of Zurich | Bacteremia | 2010-02 | PHASE2 |
| NCT03961503 | University Hospital, Montpellier | Infective Endocarditis|Infection Related to Ventricular Assist Device|Infection Related to Vascular Prothesis|Surgical Site Infection|Mediastinitis | 2016-01-01 | |
| NCT00695903 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Endocarditis, Bacterial|Infective Endocarditis | 2008-09-17 | PHASE2 |
| NCT01199783 | Ruhr University of Bochum | Diabetic Foot | 2011-07 | PHASE3 |
| NCT00490737 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | End-Stage Renal Disease | 2007-08-12 | PHASE1 |
| NCT01211470 | PolyMedix, Inc. | Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA)|(Susceptible or Methicillin Resistant) | 2010-10 | PHASE2 |
| NCT01898338 | Miquel Pujol|Hospital Universitari de Bellvitge | Staph Aureus Methicillin Resistant Bacteremia | 2013-12 | PHASE3 |
| NCT04132115 | Azienda Sanitaria-Universitaria Integrata di Udine | Therapeutic Drug Monitoring|Subarachnoid Hemorrhage|Intracerebral Hemorrhage | 2019-10-01 | |
| NCT01419184 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Staphylococcal Skin Infections | 2011-09-09 | PHASE4 |
| NCT00679835 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Gram Positive Infection|Concurrent Antibiotic Treatment | 2008-06-03 | PHASE1 |
| NCT04277143 | Zhongnan Hospital | Outcome, Fatal|Infection | 2020-12-01 | |
| NCT00261807 | University of Maryland, Baltimore|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Fasciitis, Necrotizing|Severe Necrotizing Skin and Soft Tissue Infections|Fournier´s Gangrene | 2005-06 | NA |
| NCT00701636 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)|Hartford Hospital|Western University of Health Sciences | Late Effects of Surgery|Staphylococcus Aureus|Surgical Site Infection | 2008-07 | PHASE3 |
| NCT00428844 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Osteomyelitis | 2007-06-26 | PHASE2 |
| NCT01019395 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Gram Positive Bacterial Infection | 2010-01-05 | PHASE1 |
| NCT00426933 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Soft Tissue Infections | 2007-01 | PHASE2 |
| NCT00572260 | Duke University|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Antimicrobial Prophylaxis | 2008-01 | PHASE4 |
| NCT01455246 | University of Padova | Cirrhosis|Ascites|Nosocomial Spontaneous Bacterial Peritonitis | 2010-10 | PHASE2|PHASE3 |
| NCT00772447 | AstraZeneca | Skin Diseases|Infectious | 2008-09 | PHASE3 |
| NCT01549613 | University of Cincinnati | Cellulitis|Skin Infections | 2012-05 | PHASE4 |
| NCT02052388 | Cellceutix Corporation | Skin Infection|Bacterial Infection | 2014-02 | PHASE2 |
| NCT00055198 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Gram-Positive Bacterial Infections | 2002-12-19 | PHASE3 |
| NCT01515020 | Assistance Publique - H?pitaux de Paris|Novartis | Nosocomial Infection|Healthcare-associated Infection | 2012-05 | PHASE3 |
| NCT05156437 | West Virginia University | Endocarditis | 2022-03-16 | PHASE4 |
| NCT02097953 | University of Utah|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Drug Interactions|Pharmacokinetics | 2014-05 | EARLY_PHASE1 |
| NCT00882557 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | End-stage Renal Disease|Renal Failure Chronic Requiring Hemodialysis | 2009-04-29 | PHASE1 |
| NCT05977868 | West Virginia University | Endovascular Infection|Bone and Joint Infection|Skin and Soft Tissue Infection|Pulmonary Infection|Gastrointestinal Infection|Genitourinary Infection | 2023-08-04 | PHASE4 |
| NCT00136292 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Gram-positive Bacterial Infections | 2005-08-24 | PHASE1 |
| NCT05224687 | Methodist Health System | Antibiotics Causing Adverse Effects in Therapeutic Use | 2021-12-15 | |
| NCT04298463 | Aziende Chimiche Riunite Angelini Francesco S.p.A|Hippocrates Research | Acute Bacterial Skin and Skin Structure Infection | 2020-06-18 | |
| NCT00401960 | Weill Medical College of Cornell University | Endocarditis, Bacterial | 2006-09 | PHASE4 |
| NCT01104662 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Complicated Skin and Skin Structure Infections|S. Aureus Bacteremia|Renal Impairment | 2010-04-19 | PHASE4 |
| NCT01012089 | University of Oklahoma|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Chronic Kidney Disease|Bacterial Infection | 2009-11 | NA |
| NCT00507247 | M.D. Anderson Cancer Center|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Staphylococcus Aureus | 2006-05 | PHASE2 |
| NCT00711802 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Skin Diseases, Infectious | 2008-07-23 | PHASE4 |
| NCT02972983 | McGill University Health Centre+Research Institute of the McGill University Health Centre | Methicillin Susceptible Staphylococcus Aureus Septicemia|Bacteremia | 2016-12-01 | PHASE4 |
| NCT01626560 | Hospital Universitario Evangelico de Curitiba | Cellulitis | 2012-07 | PHASE4 |
| NCT01175707 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Complicated Skin or Skin Structure Infection | 2010-07-15 | PHASE4 |
| NCT00463801 | Novartis | Staphylococcal Skin Infections | 2007-01 | PHASE4 |
| NCT04546815 | Jiangsu Hengrui Pharmaceutical Co., Ltd. | Antibiotic | 2020-08-25 | |
| NCT01922011 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Acute Hematogenous Osteomyelitis | 2013-09-13 | PHASE3 |
| NCT04983901 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC | Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm | 2021-09-14 | PHASE2 |
| NCT04434300 | University Hospital, Caen | Antibiotics|Subcutaneous Injection|Daptomycin | 2020-10-15 | PHASE1 |
| NCT00335478 | OHSU Knight Cancer Institute | Fever|Sweating|Hot Flashes|Infection|Neutropenia|Unspecified Adult Solid Tumor, Protocol Specific | 2006-12 | PHASE2 |
| NCT02660346 | Sharp HealthCare | Bacteremia | 2015-11 | PHASE4 |
| NCT01522105 | Insel Gruppe AG, University Hospital Bern | Meningitis | 2012-04 | PHASE1 |
| NCT00296049 | Wake Forest University Health Sciences|National Cancer Institute (NCI) | Infection|Neutropenia|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific | 2005-07 | NA |
| NCT02508350 | Zhongda Hospital | Septic Shock | 2015-01 | NA |
| NCT00942149 | Duke University | Sepsis | 2010-01 | PHASE1 |
| NCT00540072 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Pneumonia, Bacterial | 2001-07-30 | PHASE3 |